Tukysa Tablet
Product Images NDC 51144-002

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tukysa (NDC 51144-002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Seagen Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Tukysa 01)

Chemical structure diagram of tucatinib, the active ingredient in TUKYSA tablets. The diagram depicts the molecular arrangement and bonding of atoms in tucatinib.*

FDA Label Image

Figure 1 (Tukysa 02)

A Kaplan-Meier plot showing progression-free survival (PFS) probability over time (in months) for two treatment groups: Tuc+Tras+Pert and Pbo+Tras+Pert. The y-axis represents PFS probability, and the x-axis shows time up to 42 months. The chart includes a participants-at-risk table below the x-axis indicating the number of subjects remaining at each time point for both groups.*

FDA Label Image

Figure 2 (Tukysa 03)

A Kaplan-Meier curve chart depicting progression-free survival percentages over time in months, comparing two treatments: Tukysa combined with Tras and Cape, and a placebo combined with Tras and Cape. The graph shows the number of patients at risk at various time points for both groups, illustrating differences in survival outcomes up to 36 months.*

FDA Label Image

Figure 3 (Tukysa 03a)

A Kaplan-Meier survival curve chart depicting overall survival percentage over time in months for two groups: one treated with Tukysa (tucatinib) plus Tras and Cape, and a placebo group with Tras and Cape. The graph shows higher survival in the Tukysa group over 36 months, with a table of numbers at risk below the x-axis indicating patient counts at various time points.*

FDA Label Image

Logo (Tukysa 04)

FDA Label Image

Small Logo (Tukysa 05)

The image shows a carton package for TUKYSA (tucatinib) tablets, labeled with a strength of 150 mg. The label indicates the product is an oral tablet form by the manufacturer SEAGEN INC. The packaging includes the proprietary and generic names, dosage form, and strength, with a modern design featuring green and white colors.*

FDA Label Image

50 mg Label (Label50mg)

Label for TUKYSA tablets containing 50 mg of tucatinib, manufactured by Seagen Inc. The label includes storage instructions, dosage advisory, a warning to keep out of reach of children, and a note to discard unused tablets 3 months after opening. The package contains 60 tablets.*

FDA Label Image

150 mg Label 60 Count (Label150mg60ct)

Label for TUKYSA (tucatinib) tablets 150 mg by Seagen Inc. The label indicates the product is for oral use with 60 tablets per container. Storage instructions advise controlled room temperature, and it warns to discard unused tablets three months after opening. The label includes barcode, lot, expiration, and serial number placeholders.*

FDA Label Image

150 mg Label 120 Count (Label150mg120ct)

TUKYSA (tucatinib) 150 mg tablets packaging label, showing 120 tablets per container. The label includes storage instructions to keep at controlled room temperature between 20°C to 25°C and warnings to discard unused tablets 3 months after opening. Manufactured by Seagen Inc., USA. The label features barcode and lot, expiration, and serial number placeholders.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.